<p>Melvin Reichman of the LIMR Chemical Genomics Center Inc. in the U.S., working with Vicky Avery of the Eskitis Institute for Cell and Molecular Therapies in Australia, will develop and validate a new drug screening approach called Ultra-High Throughput Screening for Synergy (uHTSS) to discover new drug combinations from the Tres Cantos anti-malarial set for the treatment of malaria.</p>


Melvin Reichman of the LIMR Chemical Genomics Center Inc. in the U.S., working with Vicky Avery of the Eskitis Institute for Cell and Molecular Therapies in Australia, will develop and validate a new drug screening approach called Ultra-High Throughput Screening for Synergy (uHTSS) to discover new drug combinations from the Tres Cantos anti-malarial set for the treatment of malaria.